Osteoporosis: how should it be treated? (Q36583646)

15 August 2017

1 reference

title

Osteoporosis: how should it be treated? (English)

1 reference

15 August 2017

0 references

1

Clarita V Odvina

1 reference

15 August 2017

1 April 2006

1 reference

Journal of Investigative Medicine

15 August 2017

1 reference

15 August 2017

54

1 reference

15 August 2017

3

1 reference

15 August 2017

114-122

1 reference

Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age

15 August 2017

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Involutional osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Changes in bone remodeling rate influence the degree of mineralization of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Aging of microstructural compartments in human compact bone

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Fractures after long-term alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM : V. A STUDY OF THE BONE TRABECULAE AS A READILY AVAILABLE RESERVE SUPPLY OF CALCIUM

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effects of strontium ions on growth and dissolution of hydroxyapatite and on bone mineral detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F6650.2006.05037

21 January 2018

Identifiers

DOI

10.2310/6650.2006.05037

1 reference

15 August 2017

1 reference

PubMed ID

16948394